Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCTE9R)

Drug Name
Mexiletine Drug Info
Synonyms
Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene
Therapeutic ClassAntiarrhythmic Agents
Cross-matching ID
PubChem CID
4178
ChEBI ID
CHEMBL558
CAS Number
CAS 31828-71-4
TTD Drug ID
D0X0RI
VARIDT Drug ID
DR00695
INTEDE Drug ID
DR1079
ACDINA Drug ID
D00428

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.09 0.00e+0 34/36 (94.44%) FEN1;POLE2;MCM5;...
Carbohydrate digestion and absorption 1.84 3.20e-2 37/47 (78.72%) PLCB1;PIK3CD;SLC37A4;...
Base excision repair 1.81 3.36e-2 29/33 (87.88%) FEN1;POLE2;POLD3;...
Homologous recombination 1.79 3.20e-2 35/41 (85.37%) BARD1;BLM;BABAM2;...
Neutrophil extracellular trap formation 1.77 3.11e-2 101/189 (53.44%) TLR4;ITGAM;PLCB1;...
Lysine degradation 1.74 4.12e-2 51/63 (80.95%) SMYD3;ALDH3A2;EHHADH;...
Valine, leucine and isoleucine degradation 1.72 4.05e-2 42/48 (87.5%) HMGCS1;PCCB;ALDH3A2;...
Staphylococcus aureus infection 1.71 3.55e-2 72/95 (75.79%) ITGAM;CFB;DEFB1;...
African trypanosomiasis 1.70 3.87e-2 32/37 (86.49%) PLCB1;PRKCA;HBB;...
Butanoate metabolism 1.66 4.99e-2 23/28 (82.14%) HMGCS1;GAD1;EHHADH;...
Autophagy -1.75 4.49e-2 113/169 (66.86%) ULK1;RAF1;DAPK2;...
Riboflavin metabolism -1.77 4.34e-2 7/8 (87.5%) ACP1;ACP5;ENPP1
Steroid hormone biosynthesis -1.79 3.90e-2 43/61 (70.49%) UGT2B28;UGT2B17;UGT2B4;...
Mitophagy -1.96 8.13e-3 56/68 (82.35%) USP8;NRAS;TAX1BP1;...
FoxO signaling pathway -1.96 1.08e-2 118/131 (90.08%) CDKN2B;HRAS;CAT;...
Protein processing in endoplasmic reticulum -1.99 5.42e-3 127/171 (74.27%) PRKCSH;CALR;PDIA6;...
Ferroptosis -2.11 0.00e+0 36/41 (87.8%) GCLC;PCBP1;SLC3A2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H